evipedia.ai
← Back

NMN for Health & Longevity

Evidence Review created on 11/07/2026 using AI4L / Opus 5.5

Also known as: Nicotinamide Mononucleotide, β-Nicotinamide Mononucleotide, Beta-Nicotinamide Mononucleotide, β-NMN, Beta-NMN, MIB-626, Uthever

Motivation

Nicotinamide mononucleotide (NMN) is a compound derived from vitamin B3 that the body converts into a molecule every cell needs to turn food into energy and to repair its DNA. Levels of that molecule fall with age in several tissues, and NMN is sold as a daily supplement on the idea that restoring them could slow parts of the aging process.

Interest grew after long-term experiments in aging mice, followed by a run of small human trials in middle-aged and older adults that measured blood levels of the target molecule, walking and running capacity, and blood pressure. Its legal status as a supplement in the United States changed twice within three years, and much of the human research has been funded by companies that make or sell it.

This review examines what human trials, pooled analyses and laboratory studies show about NMN for health- and longevity-focused adults: which effects have been measured and how consistently, what is known and unknown about short- and long-term safety, how it is dosed and monitored, and which questions remain open.

Benefits - Risks - Protocol - Conclusion

This section lists expert overviews of NMN from priority longevity sources, each discussing NMN by name in depth.

Chris Kresser: chriskresser.com’s NMN content is a segment of a 2020 interview with David Sinclair (RHR: How to Slow Aging and Increase Healthspan, with Dr. David Sinclair) and a brief mention in a 2023 Mark Hyman interview (RHR: Unlocking the Keys to Longevity by Understanding the Root Causes of Aging, with Mark Hyman); neither is listed because Sinclair’s NMN views are already covered by the Huberman Lab entry above and the Hyman mention is too brief.

Grokipedia

Nicotinamide mononucleotide

AI-generated encyclopedia entry on β-NMN covering its biochemistry, role in NAD+ synthesis and the preclinical and human research, supported by 141 cited sources.

Examine

Nicotinamide Mononucleotide

Describes NMN as a vitamin B3 derivative taken to raise NAD+, noting that aging-related effects seen in animals remain unproven in humans; links summaries of trials and meta-analyses.

ConsumerLab

NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN)

Independent product testing of NMN and NADH (the reduced form of NAD+) products, with updates on mislabeled products, U.S. regulatory status and safety questions; full content requires membership.

Systematic Reviews

This section lists systematic reviews and meta-analyses of human NMN trials, covering safety, muscle, metabolic, blood-pressure and performance outcomes.

Mechanism of Action

The enzymes NMNAT1–3 (nicotinamide mononucleotide adenylyltransferases, which add adenine to NMN) convert NMN directly into NAD+. NAD+ carries electrons in energy metabolism and is consumed by sirtuins (protein-modifying enzymes that tune metabolism and stress responses), PARPs (poly-ADP-ribose polymerases, DNA-repair enzymes) and CD38 (an immune-cell enzyme that degrades NAD+ and rises with age). Cells normally make NMN from nicotinamide via NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of NAD+ recycling). Extra NMN aims to offset age-related NAD+ decline and restore sirtuin function (Mills 2016, Shin-ichiro Imai’s group, which earns NMN patent-licensing fees; NMN maker Oriental Yeast co-authored).

How oral NMN reaches cells is contested. Imai’s group proposed a dedicated carrier encoded by Slc12a8 (a mouse transporter gene) (Grozio 2019); another laboratory disputed that evidence (Schmidt 2019), led by Charles Brenner, an adviser to ChromaDex, maker of competing nicotinamide riboside. Alternatives are conversion outside cells to nicotinamide riboside, or by gut bacteria to nicotinic acid, which enters the Preiss-Handler pathway (the nicotinic-acid route to NAD+); a Nestlé-run trial supported the gut route (Christen 2026).

NMN is not receptor-selective, has no known cytochrome P450 (liver drug-metabolizing enzyme) metabolism or published human half-life. In mice, tissues use oral NMN for NAD+ synthesis within minutes (Mills 2016). In humans, little intact NMN reaches urine (Pencina 2023, co-authored by developer Metro International Biotech); 8 days of NMN raised blood but not brain NAD+ (Berven 2026). Surplus is methylated by NNMT (nicotinamide N-methyltransferase) and excreted as 2PY and 4PY (terminal vitamin B3 breakdown products).

Historical Context & Evolution

NMN was identified in mid-20th-century biochemistry as an intermediate in NAD+ synthesis and was long only a laboratory reagent. Its appeal for health optimization came from mouse studies: Shin-ichiro Imai’s group reported that NMN reversed features of diet- and age-induced diabetes (Yoshino 2011); David Sinclair’s group reported that raising NAD+ restored mitochondrial markers in aged muscle (Gomes 2013); and a 12-month study found NMN blunted age-related weight gain and improved insulin sensitivity, energy metabolism and eye function (Mills 2016).

Consumer products appeared before any human data; the first human safety study, a single-dose trial in ten men, was published online in 2019 (Irie 2020). Since then about 15 small randomized trials, many funded by ingredient makers, have tested NMN for 2 to 24 weeks. Their findings moved opinion from enthusiasm built on mouse data toward a narrower position: NMN reliably raises blood NAD+, while clinical effects are modest and inconsistent (Yang 2026). Supporters point to positive endurance and blood-pressure data; critics point to null muscle (Prokopidis 2025) and metabolic (Zhang 2025) meta-analyses. A preprint mouse study, co-authored by David Sinclair of NMN developer Metro International Biotech, reported longer median lifespan in females only (Kane 2024), keeping the longevity question open. Regulation shifted: the U.S. Food and Drug Administration (FDA) excluded NMN from supplements in 2022 and reversed it in 2025, as reported by trade journal Nutritional Outlook (Nutritional Outlook report); FDA’s response letter could not be retrieved; FDA’s list records β-NMN supplement-ingredient filings answered in 2026 (FDA notification list).

Expected Benefits

High 🟩 🟩 🟩

Aerobic Endurance & Walking Capacity ⚠️ Conflicted

In middle-aged adults, 600–900 mg/day for 60 days lengthened six-minute walk distance versus placebo in an Abinopharm-funded trial (Yi 2023); in amateur runners, 600–1,200 mg/day raised power at ventilatory thresholds (intensities where breathing rises disproportionately) (Liao 2021). A network meta-analysis pooled these gains (Gao 2026). Yet a 2,000 mg/day, 28-day trial co-authored by developer Metro International Biotech left aerobic capacity unchanged (Pencina 2023), and an Effepharm-funded 300 mg/day trial found no significant walking gain (Huang 2022). The net reading is a moderate endurance signal from two independent groups’ small trials.

Magnitude: Endurance SMD (standardized mean difference, effect size in standard-deviation units) 0.66 (95% CI, confidence interval, 0.09 to 1.23) at medium dose and 1.02 (95% CI 0.43 to 1.60) at high dose versus placebo (Gao 2026).

Medium 🟩 🟩

Diastolic Blood Pressure ⚠️ Conflicted

Two meta-analyses of about ten small trials each found NMN modestly lowered diastolic pressure, with systolic reductions confined to adults aged 60 and older or with metabolic risk (Zhang 2026, Yang 2026). Blood pressure was mostly a secondary endpoint, and Yang 2026 rated its certainty low. A 10-week trial in women with prediabetes, co-authored by Imai, who receives NMN patent-licensing fees from Metro International Biotech and Teijin, found no blood-pressure change (Yoshino 2021). The net reading is a small diastolic reduction, most visible in older or metabolically at-risk adults.

Magnitude: Diastolic −2.15 mmHg (95% CI −3.68 to −0.61) versus placebo (Zhang 2026) and −2.43 mmHg (95% CI −4.21 to −0.66) (Yang 2026); systolic −0.89 mmHg (95% CI −3.83 to 2.05), not significant (Yang 2026).

Self-Rated Health & Quality of Life ⚠️ Conflicted

All three NMN doses raised SF-36 scores (a validated 36-item health-status questionnaire) more than placebo at 60 days in Yi 2023, and a network meta-analysis found moderate quality-of-life gains with NMN (Gao 2026). In Huang 2022, the abstract describes SF-36 gains of 6.5% versus 3.4%, but the full text states the difference was not statistically significant. Self-reported scores in short trials are prone to expectation effects. The net reading is a moderate subjective-health signal from industry-funded trials.

Magnitude: Quality-of-life SMD 0.56 (95% CI 0.14 to 0.98) at high dose and 0.45 (95% CI 0.11 to 0.78) at low dose versus placebo (Gao 2026).

Low 🟩

Muscle Strength & Function in Older Adults ⚠️ Conflicted

Trials of 250 mg/day reported nominal gait and grip gains (Igarashi 2022, Mitsubishi co-authored) and faster 4-metre walking (Morifuji 2024, Meiji-funded), and one meta-analysis found faster gait (Wang 2025). A stricter meta-analysis found no effect (Prokopidis 2025). The net reading is no reliable strength benefit.

Magnitude: Gait speed MD (mean difference) −0.01 m/s (95% CI −0.08 to 0.06) and grip strength MD 0.61 kg (95% CI −0.89 to 2.10) versus placebo (Prokopidis 2025); gait speed SMD 0.34 (95% CI 0.03 to 0.66) (Wang 2025).

Muscle Insulin Sensitivity ⚠️ Conflicted

In 25 women with prediabetes, 250 mg/day raised muscle insulin sensitivity measured during insulin infusion (Yoshino 2021); ChromaDex adviser Charles Brenner noted unequal baseline liver fat (Brenner 2021). A meta-analysis found no HbA1c (three-month average glucose) or HOMA-IR (insulin-resistance index) (Chen 2024). The net reading is a single-trial tissue effect.

Magnitude: Insulin-stimulated glucose disposal rose 25 ± 7% after NMN and did not change after placebo, not compared between groups (Yoshino 2021); HOMA-IR MD −0.22 (95% CI −0.55 to 0.11) versus placebo (Yang 2026).

LDL Cholesterol ⚠️ Conflicted

MIB-626 (a pharmaceutical NMN), 2,000 mg/day for 28 days, lowered LDL (low-density lipoprotein) cholesterol in overweight adults (Pencina 2023), co-authored by its developer. Pooled trials found no lipid change (Zhang 2025). The net reading is no consistent lipid benefit.

Magnitude: LDL −18.73 mg/dL (95% CI −31.85 to −5.60) versus placebo (Pencina 2023); in Yi 2023, day-60 LDL was 146 mg/dL with 900 mg/day versus 119 mg/dL with placebo (p = 0.02, the probability of a difference this large arising by chance alone; baseline 133 versus 114 mg/dL), a difference in final values, not in change.

Liver Enzyme Levels ⚠️ Conflicted

A meta-analysis of nine trials in middle-aged and older adults found NMN lowered ALT (alanine aminotransferase, a liver-damage marker) (Wang 2025). A later pooled analysis found no significant change in ALT or AST (aspartate aminotransferase, a related liver enzyme) (Yang 2026). The net reading is no reliable liver-enzyme benefit.

Magnitude: ALT SMD −0.29 (95% CI −0.55 to −0.03) versus control (Wang 2025); ALT MD −1.03 U/L (95% CI −2.51 to 0.44), not significant (Yang 2026).

Sleep Quality & Daytime Drowsiness ⚠️ Conflicted

In older adults, 250 mg/day improved Pittsburgh Sleep Quality Index scores versus placebo (Morifuji 2024). In Kim 2022 (Mitsubishi co-authored), drowsiness also improved with afternoon placebo, though the abstract credits NMN. Pooled data are null (Gao 2026). The net reading is an inconsistent sleep signal.

Magnitude: No between-group difference in sleep quality in Kim 2022 (group-by-time interaction, the test of whether groups changed differently, not significant); within-group global score effect sizes (d) were 0.68 with afternoon and 0.31 with morning NMN versus 0.52 and 0.51 with afternoon and morning placebo, not compared between groups.

Speculative 🟨

Restoration of Blood & Tissue NAD+ ⚠️ Conflicted

Pooled trials show blood NAD+, an unvalidated biomarker, rises (Zhang 2025); Huang 2022’s full text, unlike its abstract, finds no significant difference. Eight days left brain NAD+ unchanged (Berven 2026). Net reading: reliable blood rise.

Lifespan Extension & Frailty Delay

In a non-peer-reviewed mouse study, long-term NMN started in middle age reduced frailty and extended female median lifespan by 8.5% (Kane 2024). No human lifespan data exist; basis is animal work only.

Biological Age Calculators

In Yi 2023, a blood-test aging calculator rose with placebo but not with NMN over 60 days. Such calculators are not validated against health outcomes.

Ovarian & Oocyte Quality ⭕️ Not Central to Health & Longevity

A systematic review of animal studies found NMN improved egg-cell mitochondrial function under aging stress (Noh 2026). This bears on female fertility; basis is animal and mechanistic only.

Benefit-Modifying Factors

  • Genetic variation: No human study links a polymorphism to NMN response. Variants in NNMT, the enzyme that methylates surplus nicotinamide for excretion, could plausibly change how much NMN-derived nicotinamide is retained, but this is untested.
  • Baseline NAD+ level: Blood NAD+ rises varied widely at the same dose (coefficient of variation, spread relative to the mean, 29–113%), and larger rises tracked larger walking and SF-36 gains (Kuerec 2024, Abinopharm co-authored); whether low starting NAD+ predicts better response is untested.
  • Sex: Human NAD+ responses did not differ by sex (Pencina 2023, Berven 2026). In mice, lifespan gains appeared only in females and metabolic gains only in males (Kane 2024).
  • Pre-existing metabolic conditions: Blood-pressure reductions were larger in overweight, prediabetic or hypertensive participants (Yang 2026); older men with diabetes and impaired physical performance gained no strength or gait benefit over 24 weeks (Akasaka 2023, Teijin co-authored).
  • Age: Systolic pressure fell only in adults aged 60 and older (Zhang 2026), yet muscle outcomes in adults over 60 were null (Prokopidis 2025), so greater age does not translate into larger functional gains.
  • Training status: Endurance gains appeared in trained runners (Liao 2021) and on a walking test in healthy middle-aged adults (Yi 2023), but not in a 28-day aerobic-capacity trial in overweight adults (Pencina 2023); no trial has compared trained with untrained participants.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been shown more often with NMN than with placebo in trials from any research group.

Medium 🟥 🟥

No risk reaches Medium: the controlled human safety data are short trials showing no excess adverse events, and the remaining concerns rest on observational metabolite associations or animal work.

Low 🟥

Gastrointestinal Upset & Headache ⚠️ Conflicted

The discussion of an NMN trial notes that high-dose nicotinamide, an NMN breakdown product, causes nausea and headache (Huang 2022). Pooled trials of 250–2,000 mg/day for up to 24 weeks found no excess gastrointestinal, nervous-system or skin events versus placebo (Yang 2026). The net reading is good short-term tolerability.

Magnitude: Total adverse events RD (risk difference) −0.008 (95% CI −0.061 to 0.045) versus control in 230 NMN and 153 control participants (Yang 2026); adverse events in 2 of 60 NMN versus 5 of 20 placebo participants (Yi 2023).

Raised Terminal Metabolites & Vascular Inflammation

NMN raises blood 2PY and 4PY dose-dependently (Irie 2020). In cardiac patients, higher 2PY and 4PY predicted major cardiovascular events, and 4PY induced vascular inflammation in mice (Ferrell 2024). The evidence is indirect: it concerns the body’s own metabolite levels, not NMN use.

Magnitude: Adjusted hazard ratio (relative event rate over time) for 3-year major adverse cardiovascular events with higher 4PY 1.89 (95% CI 1.26 to 2.84) in a U.S. cohort and 1.99 (95% CI 1.26 to 3.14) in a European cohort (Ferrell 2024); observational, with no NMN exposure measured.

Speculative 🟨

Tumor Promotion

NAD+ fuels the inflammatory secretions of senescent cells that promote tumors (Nacarelli 2019); a mouse lifespan study found no tumor increase (Kane 2024). Basis is preclinical only.

Kidney Inflammation in Aged Kidneys

In 26-month-old mice, eight weeks of NMN raised kidney inflammation and injury markers and uremic toxins (wastes normally cleared by kidneys), unlike in young mice (Saleh 2024, preprint). Basis is animal only.

Axon Degeneration via SARM1

SARM1 (an enzyme that triggers nerve-fiber self-destruction) is activated by a high NMN-to-NAD+ ratio (Figley 2021). Whether oral NMN shifts this ratio in human nerves is unknown; basis is mechanistic.

Methyl-Group Drain

Clearing NMN-derived nicotinamide consumes methyl groups; muscle N-methylnicotinamide (methylated nicotinamide) rose after NMN (Yoshino 2021). Effects on homocysteine (an amino acid that builds up when methyl groups run short) are unreported; basis is mechanistic.

Risk-Modifying Factors

  • Genetic variation: The variant rs10496731 raises circulating 2PY and 4PY and is linked to a vascular adhesion molecule (Ferrell 2024); carriers may start with higher terminal-metabolite levels. NNMT variants affecting methyl-group load are untested.
  • Baseline biomarkers: People with high homocysteine or reduced kidney function may accumulate more NMN-derived metabolites; no NMN trial has stratified risk by these markers.
  • Sex: No sex difference in adverse events has been reported; trials enrolled both sexes but were too small to detect one, and hormone-sensitive cancer risk has not been studied.
  • Pre-existing conditions: Theoretical risks concentrate in active or past cancer (preclinical tumor-promotion signals), chronic kidney disease (renal clearance of 2PY, 4PY and uremic toxins) and peripheral neuropathy (nerve damage in the hands and feet; SARM1 mechanism); none has human NMN safety data.
  • Age: The kidney-inflammation signal appeared in old but not young mice (Saleh 2024); a 24-week trial in men with a mean age of 81 reported no serious adverse events (Akasaka 2023).

Key Interactions & Contraindications

Documented interactions:

  • None identified

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Glucose-lowering drugs (metformin, insulin, glimepiride): inferred from NMN’s muscle insulin-sensitizing effect (Yoshino 2021); consequence is additive glucose lowering with hypoglycemia (low blood sugar), mainly with insulin or sulfonylureas (drugs that force insulin release); mitigated by home glucose checks during the first weeks.
  • Blood-pressure-lowering drugs (amlodipine, lisinopril, losartan): inferred from additive diastolic reduction (Yang 2026); consequence is extra blood-pressure lowering with lightheadedness on standing; mitigated by home blood-pressure checks after starting.
  • NAMPT inhibitors (FK866, an investigational anticancer agent): inferred from NMN bypassing the NAMPT step that these drugs block to starve tumors of NAD+; consequence is possible loss of anticancer effect; mitigated by pausing NMN during such therapy.
  • Over-the-counter vitamin B3 (niacin, nicotinamide, niacinamide): inferred from shared breakdown into nicotinamide, 2PY and 4PY; consequence is higher total vitamin B3 and terminal-metabolite load, plus flushing with niacin; mitigated by counting all vitamin B3 sources.
  • Other NAD+-raising supplements (nicotinamide riboside, apigenin, quercetin): inferred from additive NAD+ elevation through precursor supply or CD38 inhibition; consequence is greater metabolite and methyl-group load without tested added benefit; mitigated by not combining several NAD+-raising supplements.
  • Glucose- or blood-pressure-lowering supplements (berberine, chromium, fish oil): inferred from additive glucose or blood-pressure lowering; consequence is low blood sugar or lightheadedness in susceptible users; mitigated by home monitoring when combining.
  • Methyl donors (trimethylglycine (TMG), folate, choline): inferred from methylation-based clearance of nicotinamide; consequence is supportive, offsetting methyl-group use, though no trial has tested the pairing; no mitigation needed.
  • Intravenous NAD+ infusions: inferred from additive NAD+ and metabolite elevation; consequence is a larger terminal-metabolite load with no combined safety data; mitigated by not combining infusions with high oral doses.

Populations who should avoid NMN:

  • Active cancer or ongoing cancer treatment: inferred from preclinical data that NAD+ supports tumor-promoting senescent-cell secretions (Nacarelli 2019); no human data.
  • Pregnancy and breastfeeding: the European Food Safety Authority’s 2026 novel-food opinion judged β-NMN safe for adults excluding pregnant and lactating women (EFSA opinion); no trial has enrolled pregnant or breastfeeding women.
  • Advanced chronic kidney disease (eGFR, estimated glomerular filtration rate, a blood-test measure of kidney filtering capacity, below 30 mL/min/1.73 m², stages 4–5): inferred from renal clearance of 2PY, 4PY and uremic toxins and the aged-mouse kidney signal (Saleh 2024); no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Trial-tested starting dose: Starting at 250–300 mg/day, a dose taken for 12 weeks without adverse effects (Okabe 2022, Mitsubishi co-authored), and staying at or below 900 mg/day (Yi 2023) limits exposure to untested doses and terminal-metabolite accumulation.
  • Oral rather than sublingual form: Within an hour, sublingual (dissolved under the tongue) NMN raised 2PY and 4PY faster without raising blood NAD+ more (Wakabayashi 2026, Meiji-authored); oral capsules avoid that early rise in metabolites linked to vascular inflammation.
  • Kidney and liver checks: Baseline eGFR, creatinine and liver enzymes, repeated every 6–12 months, with use paused if eGFR falls below 60 mL/min/1.73 m², address the aged-kidney and metabolite-clearance concerns.
  • Glucose monitoring with diabetes drugs: Home glucose checks for the first 2–4 weeks when NMN is combined with insulin or sulfonylureas guard against additive hypoglycemia.
  • Pause on cancer diagnosis: Protocols pause NMN on any new cancer diagnosis or during NAD+-targeting therapy, addressing the theoretical tumor-promotion risk (Nacarelli 2019).
  • Methyl-donor support: Some practitioners pair NMN with 500–1,000 mg/day trimethylglycine to offset methyl-group use; this targets a theoretical homocysteine rise and has not been tested in trials.

Therapeutic Protocol

Doses below are cited to their source; other parameters without a citation (timing, cycling, titration steps) reflect common practice.

  • Standard supplement dose: 250–300 mg/day orally, the most-studied regimen (Okabe 2022, Morifuji 2024, Huang 2022).
  • Higher-dose regimen: 600 mg/day produced the largest blood NAD+ and walking-distance response, with no further gain at 900 mg/day (Yi 2023, Abinopharm-funded).
  • Pharmaceutical-grade regimen: MIB-626, 1,000 mg once or twice daily, used in Metro International Biotech trials (Pencina 2023); not sold commercially.
  • Proponent approach: David Sinclair has described taking about 1 g of NMN each morning (Huberman Lab episode); he is affiliated with an NMN drug developer.
  • Skeptical approach: Peter Attia’s team accepts that NMN raises blood NAD+ but calls support for its use almost entirely theoretical, questioning the walking and biological-age measures behind trial benefits (Attia article).
  • Time of day: Morning intake is common practice; one trial found afternoon intake gave the largest within-group improvements in lower-limb function and drowsiness (Kim 2022).
  • Half-life: No human plasma half-life for intact NMN is published; after stopping NMN, raised blood NAD+ declined with an estimated half-life of about six days (Berven 2026).
  • Single versus split dose: Once-daily dosing raised blood NAD+ in a dose-dependent trial (Yi 2023); 1,000 mg twice daily raised NAD+ more than once daily, though the total dose also doubled (Pencina 2023).
  • Route: Oral capsules or powder; sublingual use gave no blood NAD+ advantage (Wakabayashi 2026).
  • Genetic factors: No pharmacogenetic marker guides NMN dosing; NNMT variants and rs10496731 (Ferrell 2024) are research-stage considerations only.
  • Sex: Human NAD+ responses do not differ by sex (Berven 2026), and trials used identical doses for men and women.
  • Age: Trials in adults up to their 80s used 250 mg/day (Akasaka 2023); older users with declining kidney function typically stay at the lower end.
  • Baseline NAD+: Because responses vary widely, measuring blood NAD+ before and after 4–8 weeks allows dose adjustment (Kuerec 2024).
  • Pre-existing conditions: Prediabetes was the setting of the only directly measured muscle insulin benefit (Yoshino 2021); cancer and advanced kidney disease fall under the avoidance list.

Discontinuation & Cycling

  • Intended duration: NMN is taken long-term in longevity practice, but no published human trial exceeds 24 weeks (Yang 2026); lifelong use is untested.
  • Withdrawal effects: None reported; blood NAD+ falls back gradually, still slightly raised 11 days after stopping (Berven 2026).
  • Tapering: Not required; no rebound has been described, and trials stopped NMN abruptly.
  • Cycling: No evidence shows cycling maintains efficacy; periodic breaks to reassess benefit against baseline measures are a common practice without trial data.

Sourcing and Quality

  • β-NMN form: The β-anomer (one of two forms differing in sugar–nicotinamide bond orientation) is the biologically active form used in trials; FDA’s notification list names it (FDA notification list), as did FDA’s 2025 decision, reported by Nutritional Outlook (letter unretrievable) (Nutritional Outlook report).
  • Identity and purity testing: In 2021 testing commissioned by ChromaDex, maker of competing nicotinamide riboside, 14 of 22 NMN products sold on Amazon contained under 1% of labeled NMN (NutraIngredients report; ConsumerLab review); independent certificates of analysis address this.
  • Clinically tested ingredients: Ingredients used in published trials include Uthever from Effepharm (Huang 2022), Mitsubishi Corporation Life Sciences NMN (Okabe 2022) and Oriental Yeast NMN (Yoshino 2021); trial use is not independent quality certification.
  • Reputable brands: ConsumerLab publishes Top Picks among NMN products it has tested (ConsumerLab review); independent pharmacopeial certification is rare for NMN, so batch-level laboratory reports are the usual check.
  • Stability and storage: NMN degrades with heat and humidity; cold, sealed storage limits breakdown (FoundMyFitness clip).
  • Formulation: Capsules, powder, enteric-coated (dissolving in the intestine), liposomal (fat-encapsulated) and sublingual forms exist; only oral and sublingual forms have been compared in humans, and sublingual raised terminal metabolites faster (Wakabayashi 2026).

Practical Considerations

  • Time to effect: Blood NAD+ was still rising after 8 days of NMN (Berven 2026) and was raised at 30 days (Yi 2023); functional changes in trials appeared at 4–12 weeks (Yi 2023, Morifuji 2024).
  • Common pitfalls: Buying untested products, treating a blood NAD+ rise as proof of benefit, combining several vitamin B3 forms, and judging effects without baseline measurements.
  • Regulatory status: FDA’s 2025 citizen-petition response accepted NMN as a supplement (letter unretrievable), as reported by Nutritional Outlook (Nutritional Outlook report) and petitioner NPA (Natural Products Association), whose members sell supplements (NPA statement); FDA’s list shows answered 2026 β-NMN notifications (FDA notification list).
  • Regulatory background: FDA excluded NMN in 2022 as an article first authorized for investigation as a new drug, as reported by Nutritional Outlook (Nutritional Outlook report); the 2022 letter is not posted on fda.gov, whose notification list records later β-NMN filings (FDA notification list).
  • Drug-developer interest: Metro International Biotech, developer of the drug candidate MIB-626 (Pencina 2023), asked FDA in 2021 comments to take the drug-preclusion clause seriously, as reported by SupplySide (SupplySide report).
  • Cost and accessibility: NMN is not exceptionally expensive and is self-paid; insurers have no financial stake, while the drug developer did hold a commercial interest in its regulatory status.

Interaction with Foundational Habits

  • Sleep: Direction: possibly potentiating. NMN improved sleep-questionnaire scores in older adults (Morifuji 2024), and afternoon intake gave the largest within-group drowsiness improvement, though placebo improved too (Kim 2022); pooled data are null (Gao 2026). Proposed mechanism is NAD+-dependent sirtuin regulation of the circadian clock.
  • Nutrition: Direction: indirect. Food supplies under 2 mg/day of NMN, from edamame, broccoli and avocado (Yoshino 2021). Gut bacteria convert NMN to nicotinic acid (Christen 2026); folate, choline and betaine-rich foods support methyl-group clearance of nicotinamide.
  • Exercise: Direction: potentiating in one trial. NMN raised ventilatory-threshold power in runners during training (Liao 2021); exercise itself raises muscle NAMPT 1.46-fold (Sun 2023). No blunting of training adaptation has been reported.
  • Stress management: Direction: none documented. Stress was a secondary outcome in one trial, with no stress benefit reported in its abstract (Morifuji 2024); NAD+-sirtuin links to stress responses remain theoretical, and no cortisol data exist.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes reference points for both expected changes and safety: whole-blood NAD+, fasting glucose, home blood pressure, liver enzymes, kidney function and homocysteine. Because blood NAD+ responses vary widely between people at the same dose, the individual baseline matters more than population averages (Kuerec 2024).

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Whole-blood NAD+ No established target; track change from own baseline Expected to change; confirms uptake Specialty test; same time of day each draw; responses vary widely (Kuerec 2024)
Fasting glucose 70–99 mg/dL (standard reference range) Safety check (additive glucose lowering with diabetes drugs) 8–12 h fast; pair with fasting insulin for HOMA-IR
Blood pressure Below 120/80 mmHg (normal category, 2017 ACC/AHA guideline) Expected to change (diastolic) ACC/AHA: American College of Cardiology/American Heart Association (2017 ACC/AHA guideline), societies whose members are paid to diagnose and treat high blood pressure; conventional reference range 90–119/60–79 mmHg; seated home readings, same time daily
ALT and AST ALT 7–56 U/L; AST 10–40 U/L (standard reference range) Safety check (liver) ALT/AST: alanine and aspartate aminotransferase, liver enzymes; avoid hard exercise 48 h before
eGFR and creatinine eGFR 60 mL/min/1.73 m² or higher (standard reference range) Safety check (kidney clearance of metabolites) Pair with cystatin C in muscular individuals; stay hydrated before testing
Homocysteine 5–15 µmol/L (standard reference range) Safety check (methyl-group drain) Fasting sample; low folate or vitamin B12 also raise it

Ongoing monitoring repeats NAD+, glucose and blood pressure at 8–12 weeks, then every 6–12 months, with liver, kidney and homocysteine checks every 6 months at doses above 600 mg/day. Success means a clear NAD+ rise plus improvement in a pre-chosen functional target, with safety markers unchanged. If NAD+ has not risen after 8–12 weeks, product quality and dose are the first factors reviewed.

Qualitative markers:

  • Daytime energy and fatigue
  • Exercise endurance (for example, timed walk or cycling test)
  • Sleep quality and daytime drowsiness
  • Digestive tolerance
  • Mental clarity

Emerging Research

  • Diabetic kidney disease trial: MIB-626, 1,000 mg twice daily, versus placebo for six months in 156 adults with type 2 diabetes and kidney disease; primary endpoint urine albumin-to-creatinine ratio, a kidney-damage marker (NCT05759468; protocol Chandra 2026). A positive result would add a first organ-protection benefit; a null result would weaken organ-protection claims.
  • One-year trial in middle-aged and older adults: 240 participants, 350 mg/day for one year, primary outcome biological age (NCT06592859, registered completion December 2026). A positive result would support long-term use; a null result would undercut the short-trial signals.
  • Exercise tolerance in healthy older adults: 40-participant crossover of NMN with or without trimethylglycine versus placebo; primary outcome time to fatigue during cycling (NCT07144527). A positive result would replicate the endurance signal in older adults; a null result would downgrade it.
  • NAD+ precursors in glaucoma: Phase 2, 138 patients comparing NMN, nicotinamide riboside, nicotinamide and nicotinic acid; primary outcome visual field sensitivity (NCT06991712). A positive result would provide the first human nerve-protection endpoint; a null result would limit neural claims.
  • Heart-tissue NAD+ in cardiac surgery: Phase 2, 90 patients given MIB-626 before surgery; primary outcome NAD+ in heart muscle (NCT07013591). A positive result would confirm tissue delivery in humans; a null result would question it.
  • Cardiovascular safety of terminal metabolites: Long-term trials measuring 2PY, 4PY and vascular-inflammation markers during NMN use would test the main safety concern raised by Ferrell 2024, and could weaken the case for high doses.
  • Mechanism of uptake: If NMN works mainly through gut conversion to nicotinic acid (Christen 2026), cheaper vitamin B3 forms might match it, weakening NMN-specific claims.
  • Peer-reviewed lifespan replication: Publication and independent replication of the female-only mouse lifespan gain (Kane 2024) would strengthen or weaken the longevity rationale.

Conclusion

NMN is a vitamin B3 compound that the body turns into a key energy and repair molecule whose levels fall with age. For health-focused adults willing to pay for and track a daily supplement, the evidence separates what NMN does to blood chemistry from what it does to health. Raising that molecule in the blood is consistently achieved. The most consistent health signals are a small drop in the lower blood-pressure number and moderate gains in walking or running endurance and self-rated health, each built on small, short trials. Claims for muscle strength, response to insulin, cholesterol and sleep rest on small trials that pooled analyses have not consistently confirmed. Slower aging in people is untested; longer life has been seen only in female mice.

Short-term safety looks good: across trials lasting weeks to months, side effects were no more common than with inactive capsules. The open questions concern long-term use: breakdown products linked to blood-vessel inflammation, possible support for existing tumors, and strain on aging kidneys, all so far drawn from population studies or animal work.

Much of the human research was paid for by companies that make or sell NMN, a drug developer held a commercial interest in its legal status, and a leading critic advises a maker of a competing product. Taken together, the evidence base is early, small and mixed.

Top - Benefits - Risks - Protocol